Delving into the Latest Updates on Bevurogant with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

BI 730357, BI-730357

Target

RORγt

Action

inhibitors

Mechanism

RORγt inhibitors(RAR-related orphan receptor gamma 2 inhibitors)

Therapeutic Areas

Immune System Diseases

Active Indication

Autoimmune Diseases

Inactive Indication

Arthritis, PsoriaticChronic large plaque psoriasisPlaque psoriasis

Originator Organization

Boehringer Ingelheim GmbH

Active Organization

Boehringer Ingelheim Pharmaceuticals, Inc.

Inactive Organization

Boehringer Ingelheim GmbHBoehringer Ingelheim International GmbH

License Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC26H28N8O3S

InChIKeyHVVHIBHBDCYLDI-HNNXBMFYSA-N

CAS Registry1817773-66-2

This study is open to adults with active psoriatic arthritis who have tender and swollen joints. The purpose of this study is to find out whether a medicine called BI 730357 helps to reduce symptoms and to prevent damage to joints.
Three different doses of BI 730357 are tested. Participants are put into 4 groups by chance. Participants in 3 of the 4 groups take BI 730357. Participants in the fourth group take placebo. Participants take BI 730357 or placebo as tablets once a day. Placebo tablets look like BI 730357 tablets but do not contain any medicine.
Participants are in the study for about 4.5 months. During this time, they visit the study site about 8 times. At these visits, doctors check whether the swelling of inflamed joints has changed. The results between the BI 730357 and placebo groups are then compared. Doctors also regularly check the general health of the participants.

Start Date02 May 2022

Sponsor / Collaborator

Boehringer Ingelheim GmbH

NCT04679948

/ CompletedPhase 1

The Effect of Multiple Doses of BI 730357 on the Single Dose Pharmacokinetics of Caffeine, Warfarin, Omeprazole and Midazolam Administered Orally as a Cocktail in Healthy Subjects (an Open-label, Two-period Fixed Sequence Design Trial)

The trial will be performed to assess the influence of BI 730357 on the pharmacokinetics of caffeine, warfarin, omeprazole and midazolam.

Start Date21 Dec 2020

Sponsor / Collaborator

Boehringer Ingelheim GmbH

EUCTR2019-001684-77-HU

/ Not yet recruitingPhase 2

A 12-weeks Phase II, randomized, double-blind, placebocontrolled, parallel-group, proof-of-concept trial of BI 730357 in patients with active ankylosing spondylitis

Start Date07 Dec 2020

Sponsor / Collaborator

Boehringer Ingelheim RCV GmbH & Co. KG

100 Clinical Results associated with Bevurogant

Login to view more data

100 Translational Medicine associated with Bevurogant

Login to view more data

100 Patents (Medical) associated with Bevurogant

Login to view more data

7

Literatures (Medical) associated with Bevurogant

01 May 2025·JOURNAL OF INVESTIGATIVE DERMATOLOGY

Revisiting RORγt Inhibition in Plaque Psoriasis: Lessons Learned from BI 730357

Article

Author: Bunick, Christopher G ; Akbarialiabad, Hossein

01 Jan 2025·JOURNAL OF INVESTIGATIVE DERMATOLOGY

Phase II Randomized Trial of BI 730357, an Oral RORγt Inhibitor, for Moderate-to-Severe Plaque Psoriasis

Article

Author: Papp, Kim A ; Gooderham, Melinda J ; Korell, Julia ; Mrowietz, Ulrich ; Sofen, Howard ; Drda, Kristin ; Flack, Mary ; Gu, Hui ; Kadus, Werner ; Vangerow, Harald

TRIAL DESIGN:

This 2-part, double-blinded trial assessed the RORγt inhibitor BI 730357 in plaque psoriasis.

METHODS:

In part 1, patients were randomized 2:2:2:2:1 to 25, 50, 100, and 200 mg BI 730357 or placebo once daily (fasting conditions); nonresponders were switched to higher doses. In part 2, a separate patient set was randomized 4:4:1 to receive BI 730357 (400 mg once daily, 200 mg twice daily) or a placebo (fed conditions). Patients from parts 1 and 2 could enter a long-term extension trial. Coprimary endpoints included ≥75% reduction from baseline in PASI75 and static Physician's Global Assessment score of 0/1 (clear/almost clear) at week 12.

RESULTS:

In total, 274 patients were treated (178 [part 1] and 96 [part 2]). In part 1, 12 (30.0%) patients achieved PASI75 (P = .0062), and 11 (27.5%) achieved static Physician's Global Assessment of 0/1 (P = .0095) with BI 730357 200 mg versus none receiving placebo. Exposure-response relationship plateaued at ≥200 mg once daily BI 730357. Drug-related adverse events occurred in ≤15.8% of patients. Of 165 patients who entered the long-term extension, 93 (56.4%) achieved PASI75 during treatment, and ≤18.5% experienced a drug-related adverse event.

CONCLUSIONS:

BI 730357 was well tolerated, with moderate efficacy versus placebo in plaque reduction (clinicaltrials.gov: NCT03635099 and NCT03835481).

01 Feb 2024·Clinical pharmacology in drug development

The Effect of BI 730357 (Retinoic Acid‐Related Orphan Receptor Gamma t Antagonist, Bevurogant) on the Pharmacokinetics of a Transporter Probe Cocktail, Including Digoxin, Furosemide, Metformin, and Rosuvastatin: An Open‐Label, Non‐randomized, 2‐Period Fixed‐Sequence Trial in Healthy Subjects

Article

Author: Huang, Fenglei ; Choi, HeeJae ; Flack, Mary

Abstract:

Evaluating Drug‐Drug Interactions (DDIs) for new investigational compounds requires several trials evaluating different drugs with different transporter specificities. By using a cocktail of drugs with different transporter specificities, a single trial could evaluate the pharmacokinetics (PKs) of each cocktail drug simultaneously, reducing the number of clinical DDI trials required for clinical development. We aimed to investigate the effect of steady‐state Boehringer Ingelheim (BI) 730357 (bevurogant) on the PKs of a validated and optimized 4‐component transporter cocktail. This open‐label, non‐randomized, 2‐period fixed‐sequence phase I trial compared transporter cocktail (0.25 mg digoxin/1 mg furosemide/10 mg metformin hydrochloride/10 mg rosuvastatin) with and without BI 730357 in healthy subjects aged 18‐55 years with body mass index 18.5‐29.9 kg/m2. During reference treatment/period 1, transporter cocktail was administered 90 minutes after breakfast. After a washout period, during test treatment/period 2, BI 730357 was dosed twice daily for 13 days, with transporter cocktail administered on day 1. The primary endpoints were the area under the concentration‐time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0‐∞) and the maximum measured concentration of the analyte in plasma (Cmax), and the secondary endpoint was the area under the concentration‐time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0‐tz). Steady‐state BI 730357 increased digoxin (+48% to +94%), minimally affected metformin (−2% to −9%), furosemide (+12% to +18%), and rosuvastatin (+19% to +39%) exposure. Therefore, no clinically relevant inhibition of transporters OCT2/MATE‐1/MATE‐2K, OAT1/OAT3, OATP1B1/OATP1B3 was observed. Potential inhibition of breast cancer resistance protein noted as PK parameters of coproporphyrin I/III (OATP1B1/OATP1B3 biomarkers) remained within bioequivalence boundaries while rosuvastatin PK parameters (AUC0‐∞/Cmax/AUC0‐tz) exceeded the bioequivalence boundary. BI 730357 was safe and well tolerated. This trial confirms the usefulness and tolerability of the transporter cocktail consisting of digoxin, furosemide, metformin, and rosuvastatin in assessing drug‐transporter interactions in vivo.

1

News (Medical) associated with Bevurogant

18 Jun 2021

·www.globenewswire.com

Axial Spondyloarthritis Pipeline: Drug Pipeline, Regulatory Events and Clinical Trials in the Spotlight| Insights by DelveInsight

Los Angeles, June 17, 2021 (GLOBE NEWSWIRE) -- Axial Spondyloarthritis Pipeline: Drug Pipeline, Regulatory Events and Clinical Trials in the Spotlight| Insights by DelveInsight The report offers the most up-to-date information on Axial Spondyloarthritis pipeline products being developed by notable companies such as Pfizer, Suzhou Zelgen Biopharmaceuticals, Clover Biopharmaceuticals, FunPep Co Ltd., Kinevant Sciences, Izana Bioscience, Mycenax Biotech, and UCB Biopharma, among others. DelveInsight’s ‘Axial Spondyloarthritis (axSpA) Pipeline Insights’ report offers exhaustive coverage of the emerging therapies in different stages of development from pre-clinical till late-stage, along with dormant, inactive, and abandoned therapeutic agents. Some of the important takeaways from the Axial Spondyloarthritis Pipeline report: Request for Sample to know more about the therapies expected to make grab the maximum patient pool @ Axial Spondyloarthritis Emerging Therapies and Forecast The Axial Spondyloarthritis Pipeline reports lay down a thorough coverage of the ongoing clinical trials, collaborations taking place in the domain, recent happenings in the Axial Spondyloarthritis pipeline space, and growth prospects across the Axial Spondyloarthritis domain. Axial Spondyloarthritis: Overview Axial Spondyloarthritis is a chronic, inflammatory rheumatic disease that affects primarily the axial joints leading to severe pain, stiffness, and fatigue. It starts with an early inflammatory phase in which there is no structural damage in the sacroiliac joints (non-radiographic disease) progressing to later stages in which structural damage is visible on X‑ray scans of the sacroiliac joints as erosions, sclerosis, or bony bridges (radiographic disease; also known as Ankylosing Spondylitis). Discover more about the disease, treatments, and pipeline therapies @ axSpA Pipeline Assessment Axial Spondyloarthritis Pipeline Drugs Request for Sample to know more @ Axial Spondyloarthritis Pipeline Analysis, Key Companies, and Futuristic Trends Axial Spondyloarthritis Therapeutics Assessment The Axial Spondyloarthritis Pipeline report presents a kaleidoscopic view of the axSpA emerging novel therapies segmented by Stage, Product Type, Route of Administration (RoA), Molecule Type, Target, and Mechanism of Action. By Product Type By Stage By Molecule Type By Route of Administration By Mechanism of Action By Targets For rich insights into merging therapies and assessment, visit Axial Spondyloarthritis Pipeline: Emerging Novel Therapies Scope of the Axial Spondyloarthritis Pipeline Report Coverage: GlobalKey Players: Izana Bioscience, UCB, Sun Pharma Global, Akeso Biopharma, Kinevant Sciences, Jiangsu Hengrui Medicine Co., Suzhou Zelgen Biopharmaceuticals, Clover Biopharmaceuticals, Mycenax Biotech, Boehringer Ingelheim, and Qyuns Therapeutics among others.Key Axial Spondyloarthritis Pipeline Therapies: Namilumab , Bimekizumab, Tofacitinib, Tildrakizumab, AK-111, NDI 031232, Gimsilumab, QX002N, SHR-0302, Jaktinib, SCB-808, FPP003, KIN-1901, ENIA11, BI 730357, and QX002N among others. Discover more about the report offerings @ axSpA Emerging Therapies, Treatments, and Ongoing Clinical Trials Table of Contents Get in touch with our Business executive for Regulatory Analysis, Licensing Services, and Consulting Solutions Related Reports Axial Spondyloarthritis MarketDelveInsight's "Axial Spondyloarthritis Market Insights, Epidemiology, and Market Forecast-2030" report. Non-Radiographic Axial Spondyloarthritis MarketDelveInsight's "Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Market Insights, Epidemiology, and Market Forecast-2030" report. Spondylolisthesis Market InsightsDelveInsight's “Spondylolisthesis Market Insights, Epidemiology, and Market Forecast-2030" report. Ankylosing Spondylitis MarketDelveInsight’s ‘Ankylosing Spondylitis Market Insights, Epidemiology, and Market Forecast–2030’ report. Global Kinase Inhibitor In Autoimmune Diseases MarketDelveInsight’s ‘Global Kinase Inhibitor in Autoimmune Diseases Market Insights and Market Forecast – 2030’ report. Adenosine Deaminase Severe Combined Immunodeficiency MarketDelveInsight's "Adenosine Deaminase-Severe Combined Immunodeficiency Market Insights, Epidemiology, and Market Forecast-2030" report. Adult-Onset Still Disease MarketDelveInsight’s “Adult-onset Still’s Disease Market Insights, Epidemiology, and Market Forecast – 2030” report. Browse through our posts ABSSSI Pipeline Analysis Parkinson's Disease Risk FactorsWearable Healthcare Devices Market About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. For more insights, visit Pharma, Healthcare, and Biotech News

Collaborate

100 Deals associated with Bevurogant

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Arthritis, Psoriatic	Phase 2	-	Boehringer Ingelheim GmbH	02 May 2022
Chronic large plaque psoriasis	Phase 2	United States	Boehringer Ingelheim GmbH	17 Sep 2018
Chronic large plaque psoriasis	Phase 2	Canada	Boehringer Ingelheim GmbH	17 Sep 2018
Chronic large plaque psoriasis	Phase 2	Germany	Boehringer Ingelheim GmbH	17 Sep 2018
Plaque psoriasis	Phase 2	United States	Boehringer Ingelheim GmbH	17 Sep 2018
Plaque psoriasis	Phase 2	Canada	Boehringer Ingelheim GmbH	17 Sep 2018
Plaque psoriasis	Phase 2	Germany	Boehringer Ingelheim GmbH	17 Sep 2018
Autoimmune Diseases	Preclinical	United States	Boehringer Ingelheim Pharmaceuticals, Inc.	05 Jan 2021

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03804671 (CTgov)	Phase 1	-	6	BI 730357 mixed with [C-14] BI 730357 BS	jnhhnifqhs(uqanijlevy) = ictzqacqpj orjdtbqobw (utbugpinsq, gsxxbmzdpb - vrwdregisy) View more	-	25 Jul 2023
NCT03886272 (CTgov)	Phase 1	-	43	BI 730357 (50 mg BI 730357 iCF (T1))	btjnowtugt(yiggfqwrxi) = bnsgivzihr qtttvmxsmz (pqdbgfhvqs, NA) View more	-	17 Jul 2023
				BI 730357 (50 mg BI 730357 TF1 (R1))	btjnowtugt(yiggfqwrxi) = ntxggmyffe qtttvmxsmz (pqdbgfhvqs, NA) View more
NCT04147260 (CTgov)	Phase 1	-	85	Placebo (Placebo QD)	iajugckkva(evfrwmoelc) = dycyzgkafd exrsovvahq (qnjykhtoaw, mfjdmqalwl - guzdsgtcwj) View more	-	17 Jul 2023
				BI 730357 (400 mg QD BI 730357)	iajugckkva(evfrwmoelc) = appnwzliyp exrsovvahq (qnjykhtoaw, dxuwvcspcc - aywrmcdvyy) View more
NCT03782987 (CTgov)	Phase 1	-	14	itraconazole+BI 730357 (BI 730357 + Itraconazole (T))	ggqsdlwqzw(muexvpcpjm) = ewercdnbip gpotprohui (wyiulclyxd, NA) View more	-	12 Jul 2023
				BI 730357 (BI 730357 (R))	ggqsdlwqzw(muexvpcpjm) = wxgsmcfoor gpotprohui (wyiulclyxd, NA) View more
NCT03793621 (CTgov)	Phase 1	-	24	Placebo	qvgntwmvmr = jokrpoftyh olrrmcrniu (dmijvjwtpx, dddfskeyug - sfdgqqrkxv) View more	-	12 Jul 2023
NCT03664011 (CTgov)	Phase 1	-	6	[C-14\] BI 730357+BI 730357 BS (BI 730357)	kaevswhqam(iahufmttzv) = qkmncujsed bfhehjmurq (ktboqhafyw, 19.2) View more	-	12 Jul 2023
				BI 730357 (14C-BI 730357-EQ and BI 730357)	clldjsezks(vwbavehdsn) = nyobtmioix wzpwkdvwdh (aflwwpdlou, 16.5) View more